HighTide Therapeutics

HighTide Therapeutics Announces NDA Acceptance for HTD1801 Highlights: • 3 Phase III trials met endpoints • Benefits across the CKM spectrum • First-in-class New Molecular Entity #HTD1801 #Biopharma #ClinicalTrials #DrugDevelopment #Diabetes 🔗hightidetx.com

HighTide Therapeutics (2511.HK) names Dr. Filip Surmont as Chief Medical Officer, strengthening its global clinical development and CKM disease portfolio. #biotech #PharmaLeadership #clinicaldevelopment #HealthcareInnovation #PharmaNews #healthcare

🌐HighTide Therapeutics Presents Renal Data for HTD1801, Reinforcing Its Potential as a Foundational CKM Therapy at CVCT Forum. Follow us for more updates. #HightideTherapeutics #CVCT2025 #HTD1801 #CKM #KidneyHealth #Cardiometabolic #ClinicalResearch

Post 🌐HighTide will present multifaceted CKM evidence for HTD1801 at CVCT 2025! 🎤Late-Breaking Oral Presentation Dec 9 | 08:30–10:30 ET 📌 Poster Presentation Dec 8–10 📍 Washington DC, US We look forward to sharing more insights from the event. @HighTideThera #HTD1801

HighTide Therapeutics’ HTD1801 Achieves Greater HbA1c Reduction & Superior Cardiometabolic Marker Improvement Versus Dapagliflozin in Phase III Head-to-Head Trial ✔ Greater HbA1c reduction ✔ Superior cardiometabolic improvements versus dapagliflozin ✔ Favorable safety profile

🚨 Late-Breaking @ASNKidney 2025! New data from @HighTideThera show #HTD1801 improves eGFR in patients with mild renal impairment — the first clinical evidence of potential kidney benefit in early #CKD. 📍Poster #TH-PO1190 | 🗓️Nov 6 | 10AM–12PM

📣 Late-Breaking at #ASN2025! Excited to share new evidence of kidney benefit with #HTD1801 in patients with mild renal impairment. 📅 Nov 6 | 🕙 10AM–12PM (CT) 📍 Houston, TX 🧪 Poster TH-PO1190 Join us at #KidneyWeek as we advance innovation in #renalhealth.

Major Milestone for HighTide Therapeutics Breakthrough in #Type2Diabetes! HighTide has completed two Phase 3 trials — SYMPHONY-1 & SYMPHONY-2 — for #HTD1801, a first-in-class anti-inflammatory metabolic modulator, showing durable 52-week efficacy & multi-system benefits.

Could adding a dual-action metabolic modulator to #obesity medication drive enhanced weight loss & glycemic control, with added cardiovascular benefits? Don't miss Leigh's presentation at the @HansonWade Obesity & Weight Loss Drug Development Summit today.

HTD1801 continues to show promise as a treatment for complex metabolic diseases, meeting its Phase 3 primary endpoints as a monotherapy for Type 2 #diabetes. See the results presented in a late-breaking abstract at #ADA2025: hightidetx.com/blog/2025/06/2…

We've got two posters at #EASLCongress today presenting Phase 2 trial data & post-hoc analysis of our gut-liver metabolic modulator HTD1801 in patients with at-risk #MASH + #T2DM, and in patients with #diabetes & presumed #MASLD 📌 SAT-440 📌 SAT-432

We're excited to be in Amsterdam for #EASLCongress! Stop by our poster tomorrow to see promising new preclinical data on Rimtoregtide (HTD4010), an immunomodulatory peptide that may offer new hope in treating #hepatitis & other acute liver conditions 📌 FRI-141 | 8:30 am

Presented today at #DDW2025: Preclinical results for rimtoregtide (HTD4010) show protective effects in an acute #pancreatitis model in rats, with potential implications in other acute inflammatory conditions. Learn more: hightidetx.com/news/

HighTide will present three exciting datasets at #EASLCongress, including: 💊Phase 2 post-hoc analyses for HTD1801 in #MASH + #T2DM 💊Preclinical data on HTD4010 in acute liver failure 🔗 Details here: hightidetx.com/blog/2025/04/2…

Phase 3 results for berberine ursodeoxycholate (HTD1801) are in—and they’re compelling. The dual mechanism oral therapy met primary & secondary endpoints in two trials in Type 2 #diabetes patients, with favorable safety. NDA submission in sight. hightidetx.com/blog/2025/04/1… $2511.HK

Phase 2 RCT: Berberine ursodeoxycholate (HTD1801) improves HgbA1c and a range of glycemic, cardiometabolic, and hepatic parameters at 12 weeks, supporting HTD1801 as a potential novel oral treatment option for patients with type 2 diabetes. ja.ma/4kmH6AQ @HighTideThera

𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗔𝗟𝗘𝗥𝗧: Data from the Phase 2 study of berberine ursodeoxycholate (HTD1801) for the treatment of type 2 #diabetes has been published in @JAMANetworkOpen. Read the text: jamanetwork.com/journals/jaman…

We are pleased to announce the completion of patient enrollment in the HARMONY trial, a Phase III study evaluating berberine ursodeoxycholate (HTD1801), against dapagliflozin for Type 2 diabetes. Final results are anticipated in 2025. ir.hightidetx.com